Prepared by:
Evidence Synthesis Program (ESP) Coordinating Center
Portland VA Health Care System
Portland, OR
Mark Helfand, MD, MPH, MS, Director
Recommended Citation:
Mackey K, Veazie S, Anderson J, Bourne D, and Peterson K. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2019.
Download PDF: Brief, Supplemental Materials
The ESP Coordinating Center (ESP CC) is responding to a request from VA's Health Services Research and Development Service (HSR&D) for an evidence brief on barriers to and facilitators of use of buprenorphine and extended-release naltrexone for treatment of opioid use disorder (OUD). This review synthesizes evidence on the barriers and facilitators at the patient, provider, and health care system levels. Findings from this review will be used to inform prioritization of questions for a September 2019 State-of-the-Art (SOTA) conference.
Key Question 1: What are the patient, provider, and systems-level barriers and facilitators to use of buprenorphine and extended-release naltrexone for OUD?
Key Question 2: Do these barriers and facilitators vary by patient characteristics, provider characteristics, or setting?
Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder (Management eBrief)
Mackey K, Veazie S, Anderson J, Bourne D, and Peterson K. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: A Rapid Review. Journal of General Internal Medicine. 2020;35:954-963. DOI: https://doi.org/10.1007/s11606-020-06253-8
